Wisconsin Patent of the Month – July 2024
Quincy Bioscience, LLC, a biotechnology company focused on cognitive function, has pioneered a groundbreaking composition aimed at addressing symptoms and disorders associated with cell death following ischemia.
This innovative formulation combines apoaequorin and vitamin D, delivered in precise therapeutic doses via a nutraceutical composition. Apoaequorin, a protein originally derived from luminescent jellyfish, plays a pivotal role by maintaining calcium homeostasis, crucial for neuronal excitability and muscle function. When calcium imbalances occur, they can lead to severe conditions such as neurodegenerative diseases and cardiovascular issues.
Vitamin D, known for its role in bone health and immune function, complements apoaequorin’s action by promoting calcium absorption and cellular processes critical for overall well-being. By combining these ingredients, Quincy Bioscience’s composition not only aims to prevent and alleviate calcium imbalance-related disorders but also targets symptoms like sleep disturbances, low energy levels, mood fluctuations, pain perception, and memory decline. These benefits are crucial for enhancing both physical and mental health.
The method of administration is straightforward, involving the consumption of a unit dosage form, such as a capsule, ensuring convenience and precise delivery of the therapeutic agents. This approach not only enhances bioavailability but also minimizes potential side effects associated with traditional treatments. Quincy Bioscience’s invention represents a significant advancement in nutraceutical science, offering a promising alternative for individuals seeking effective and safe solutions to manage calcium imbalance and vitamin D deficiency-related conditions.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
